Our Pricing

Wegovy vs Mounjaro Effectiveness: UK Clinical Evidence

Understanding Wegovy vs Mounjaro effectiveness UK clinical evidence helps you make an informed choice between these two licensed weight loss treatments. Both medications are approved by the MHRA for chronic weight management, but head-to-head trial data reveals significant differences in average weight loss outcomes, with tirzepatide (Mounjaro) demonstrating superior results in multiple studies [1][2].

Clinical Trial Evidence: Wegovy vs Mounjaro Effectiveness

The most compelling evidence comparing Wegovy vs Mounjaro effectiveness comes from the SURPASS-2 trial, which directly compared tirzepatide against semaglutide 1mg in patients with type 2 diabetes [1]. At 40 weeks, participants receiving the highest tirzepatide dose (15mg) achieved an average body weight reduction of 11.2kg, compared to 5.7kg with semaglutide 1mg — nearly double the weight loss [1].

In obesity-specific trials, the SURMOUNT-1 study demonstrated that tirzepatide produced average weight reductions of up to 22.5% from baseline over 72 weeks at the 15mg dose [2]. By comparison, the STEP-1 trial showed semaglutide 2.4mg (Wegovy's active ingredient) achieved an average 14.9% weight reduction over 68 weeks [3]. Both figures represent significant clinical outcomes, but tirzepatide consistently outperformed semaglutide across multiple endpoints.

It's important to note that individual results vary considerably based on adherence, lifestyle modifications, baseline BMI, and metabolic factors. These trial averages represent outcomes in controlled clinical settings with structured dietary and exercise programmes [2][3]. Your UK prescriber will assess which treatment aligns best with your medical history and weight management goals.

How Mounjaro and Wegovy Work Differently

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone. This single-pathway mechanism slows gastric emptying, reduces appetite signals to the brain, and improves insulin secretion [3]. Semaglutide has been used in diabetes management for years before receiving MHRA approval for weight management.

Mounjaro's active ingredient, tirzepatide, represents a newer pharmacological approach as the first dual GIP/GLP-1 receptor agonist licensed in the UK [1]. Beyond activating GLP-1 receptors like semaglutide, tirzepatide also stimulates glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism enhances metabolic effects, potentially explaining the superior weight loss outcomes observed in clinical trials [2].

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. The dosing schedules differ slightly: Wegovy follows a fixed escalation protocol reaching 2.4mg, whilst Mounjaro offers flexible dosing from 2.5mg up to 15mg depending on individual tolerance and response [1][3]. All prescription decisions require clinical assessment by a UK-registered prescriber.

Mechanism of Action: Why Dual Agonism Matters

The GIP receptor pathway, uniquely targeted by tirzepatide, plays a crucial role in fat metabolism and energy expenditure. Preclinical research suggests GIP activation may enhance the weight loss effects of GLP-1 stimulation, though the exact mechanisms in humans remain under investigation [2]. This dual-receptor approach represents a significant pharmaceutical advancement in obesity pharmacotherapy, offering UK patients a treatment option with enhanced efficacy compared to single-pathway alternatives.

Wegovy vs Mounjaro Effectiveness: Side Effect Profiles

Both tirzepatide and semaglutide share similar gastrointestinal side effect profiles, as expected with GLP-1 receptor agonists. The most commonly reported adverse events in clinical trials include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][3]. These effects typically occur during dose escalation and tend to diminish over time as your body adjusts to the medication.

In the SURPASS-2 head-to-head trial, discontinuation rates due to adverse events were comparable between tirzepatide and semaglutide groups, suggesting similar overall tolerability despite tirzepatide's dual mechanism [1]. Approximately 4-7% of participants discontinued tirzepatide due to gastrointestinal side effects, compared to 3-4% with semaglutide [1][3].

Rare but serious risks associated with both medications include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies). Neither medication should be used if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2][3]. Your UK prescriber will conduct a thorough medical history assessment before prescribing either treatment.

Managing Side Effects During Treatment

Starting at lower doses and following the prescribed escalation schedule significantly reduces the likelihood of severe gastrointestinal symptoms. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise nausea. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis, contact your prescriber immediately. At Cured Pharmacy, our clinical team remains available to support you throughout your treatment journey, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all prescription services.

Cost Comparison: Wegovy vs Mounjaro UK Pricing

At Cured Pharmacy, Mounjaro is available from £135.00 per month, making it accessible for UK patients seeking the most effective weight loss medication currently licensed [2]. This transparent upfront pricing includes your medication and free online consultation with a UK-registered prescriber — no hidden fees or surprise charges at checkout.

Wegovy typically costs less per month than Mounjaro across UK online pharmacies, reflecting the difference in manufacturing costs and market positioning between the two treatments. However, when evaluating value, consider the clinical effectiveness data: if tirzepatide produces significantly greater weight loss for your individual circumstances, the cost-per-kilogram lost may actually favour Mounjaro despite the higher monthly price.

Neither medication is routinely available on NHS prescription for weight management alone, though some Clinical Commissioning Groups may fund them in specific circumstances under specialist supervision. Most UK patients access these treatments through private prescriptions via registered online pharmacies like Cured Pharmacy, where you benefit from competitive pricing, discreet delivery, and ongoing clinical support.

Who Should Choose Mounjaro Over Wegovy?

Clinical trial evidence suggests tirzepatide may be particularly suitable for patients who require maximum weight loss efficacy, especially those with higher baseline BMI or those who have not achieved adequate results with other interventions [2]. If you have type 2 diabetes alongside obesity, tirzepatide's superior glycaemic control demonstrated in the SURPASS trials may offer additional metabolic benefits [1].

Wegovy remains an excellent choice for many UK patients, particularly those seeking a well-established treatment with extensive real-world safety data. Semaglutide has been used in diabetes management since 2018, providing years of post-marketing surveillance that newer medications like tirzepatide have not yet accumulated. Some patients may also find the lower cost more sustainable for long-term weight management.

Ultimately, the decision between Mounjaro and Wegovy should be made in consultation with a UK prescriber who can assess your complete medical history, current medications, contraindications, and personal preferences. At Cured Pharmacy, our online consultation process takes under three minutes and connects you with experienced clinicians who specialise in weight management prescribing. All consultations are free, with no obligation to proceed if the treatment is not deemed suitable.

Contraindications and Precautions

Both medications are contraindicated in pregnancy, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation [2][3]. Neither medication should be used if you have a history of severe gastrointestinal disease, diabetic retinopathy complications, or previous serious hypersensitivity reactions to GLP-1 receptor agonists. Your prescriber will evaluate all relevant medical factors before issuing a prescription.

Starting Treatment: What to Expect

If prescribed Mounjaro, you'll begin with a 2.5mg dose administered once weekly for four weeks, then escalate to 5mg for the next four weeks [2]. Your prescriber may continue increasing the dose in 2.5mg increments every four weeks based on your tolerance and weight loss progress, up to a maximum of 15mg weekly. This gradual escalation minimises gastrointestinal side effects whilst optimising efficacy.

Wegovy follows a similar escalation protocol, starting at 0.25mg weekly and increasing monthly until reaching the maintenance dose of 2.4mg [3]. Most patients tolerate the escalation well, though some may need to remain at a lower dose temporarily if side effects occur. Missing doses or inconsistent administration can reduce effectiveness, so establishing a weekly routine is important for optimal results.

Both treatments work best when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating the impressive weight loss figures included structured lifestyle interventions alongside medication [1][2][3]. Your prescriber may recommend working with a dietitian or weight management programme to maximise your outcomes. At Cured Pharmacy, we provide guidance resources to support your treatment journey, and our clinical team can answer questions about diet, exercise, and medication administration throughout your prescription period.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results with Wegovy and Mounjaro vary based on adherence, lifestyle modifications, baseline health status, and metabolic factors. Clinical trial data represents average outcomes in controlled study conditions and may not reflect real-world results. Neither medication is suitable for everyone, and your prescriber will evaluate contraindications, drug interactions, and medical history before issuing a prescription.